Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Well, reading the newest office action ...
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Page 11 item 19 says...

"Claims 4.7.8.10 and 14-25 are rejected under 36 USC 102(e)

as being anticipated by Kajigaya et al. (U.S. Patent Number

4,956,811 hereafter "Kajigaya")

This is, IMO, our main hurdle...although not mentioned tilll the end of the patent as you state...the examiner is telling us its the "obviousness" of the Kajigaya that is the basis of the rejections..for the most part.

I also believe we have good attorneys but their job now is to fight the anticipated/obviousness of the Kajigaya.

2 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply